BR112019004299A2 - peptídeos de nnif e relacionados a nnif e métodos relacionados - Google Patents

peptídeos de nnif e relacionados a nnif e métodos relacionados

Info

Publication number
BR112019004299A2
BR112019004299A2 BR112019004299A BR112019004299A BR112019004299A2 BR 112019004299 A2 BR112019004299 A2 BR 112019004299A2 BR 112019004299 A BR112019004299 A BR 112019004299A BR 112019004299 A BR112019004299 A BR 112019004299A BR 112019004299 A2 BR112019004299 A2 BR 112019004299A2
Authority
BR
Brazil
Prior art keywords
nnif
methods
peptides
cancer
patients
Prior art date
Application number
BR112019004299A
Other languages
English (en)
Inventor
S Weyrich Andrew
Con Yost Christian
A Zimmerman Guy
Schiffman Joshua
Original Assignee
The Univ Of Utah Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Univ Of Utah Research Foundation filed Critical The Univ Of Utah Research Foundation
Publication of BR112019004299A2 publication Critical patent/BR112019004299A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

peptídeos de fator inibidor de net neonatal (nnif) e relacionados a nnif (nrps) são fornecidos. métodos para o tratamento e a profilaxia contra distúrbios inflamatórios e câncer também são fornecidos. adicionalmente, métodos para a inibição de metástase em pacientes tendo câncer são fornecidos. os métodos podem incluir administrar um nnif e/ou um nrp a pacientes tendo, ou em risco de desenvolver, um distúrbio inflamatório ou um câncer.
BR112019004299A 2016-09-02 2017-09-05 peptídeos de nnif e relacionados a nnif e métodos relacionados BR112019004299A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662383243P 2016-09-02 2016-09-02
US201762492019P 2017-04-28 2017-04-28
PCT/US2017/050072 WO2018045371A2 (en) 2016-09-02 2017-09-05 nNIF AND nNIF-RELATED PEPTIDES AND RELATED METHODS

Publications (1)

Publication Number Publication Date
BR112019004299A2 true BR112019004299A2 (pt) 2019-05-28

Family

ID=61309026

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019004299A BR112019004299A2 (pt) 2016-09-02 2017-09-05 peptídeos de nnif e relacionados a nnif e métodos relacionados

Country Status (13)

Country Link
US (1) US10857201B2 (pt)
EP (1) EP3506924A4 (pt)
JP (1) JP2019534247A (pt)
KR (1) KR20190045271A (pt)
CN (1) CN109937047A (pt)
AU (1) AU2017321965A1 (pt)
BR (1) BR112019004299A2 (pt)
CA (1) CA3035770A1 (pt)
MX (1) MX2019002479A (pt)
RU (1) RU2019109049A (pt)
SG (1) SG11201901830UA (pt)
WO (1) WO2018045371A2 (pt)
ZA (1) ZA201901942B (pt)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11324801B2 (en) 2016-09-02 2022-05-10 University Of Utah Research Foundation NNIF and nNIF-related peptides and related methods

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4146237A1 (en) * 2020-05-04 2023-03-15 University of Utah Immunothrombosis in covid-19 acute respiratory distress syndrome
CN117004744B (zh) * 2022-04-27 2024-05-24 数字碱基(南京)科技有限公司 一种基于血浆微生物dna特征的肺癌预后评估方法及模型

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799766B2 (en) * 1998-04-08 2010-09-21 Theta Biomedical Consulting & Development Co., Inc. Composition for treating hormonally-dependent cancers
US9308235B2 (en) * 2012-05-09 2016-04-12 Spectrum Pharmaceuticals, Inc. Treatment of primary and metastatic carcinoma
EP4219534A3 (en) * 2013-07-08 2023-09-27 The University of Utah Research Foundation Methods for treatment of and prophylaxis against inflammatory disorders

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11324801B2 (en) 2016-09-02 2022-05-10 University Of Utah Research Foundation NNIF and nNIF-related peptides and related methods

Also Published As

Publication number Publication date
CN109937047A (zh) 2019-06-25
RU2019109049A3 (pt) 2020-12-24
US10857201B2 (en) 2020-12-08
EP3506924A4 (en) 2020-05-20
EP3506924A2 (en) 2019-07-10
MX2019002479A (es) 2019-09-19
US20190201487A1 (en) 2019-07-04
WO2018045371A2 (en) 2018-03-08
WO2018045371A3 (en) 2018-04-12
RU2019109049A (ru) 2020-10-05
CA3035770A1 (en) 2018-03-08
JP2019534247A (ja) 2019-11-28
AU2017321965A1 (en) 2019-04-04
SG11201901830UA (en) 2019-03-28
KR20190045271A (ko) 2019-05-02
ZA201901942B (en) 2020-10-28

Similar Documents

Publication Publication Date Title
CY1125144T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρηση αυτης
CL2018001897A1 (es) Composiciones para modular la expresión de sod-1 (divisional solicitud 201602509)
CL2018003142A1 (es) Moduladores de la vía de estrés integrada
WO2018022668A3 (en) NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
BR112017018954A2 (pt) uso de forma mutante de proteína ras e método para tratar câncer
DK3377637T3 (da) Sammensætninger til anvendelse i fremgangsmåder til behandling af sår, lidelser og sygdomme i huden
EA201790398A1 (ru) Способы лечения заболевания печени
EA201790660A1 (ru) Ингибитор киназ
GT201200318A (es) Anticuerpos hacia gdf8 humano
MY195437A (en) Methods of Treatment for Cholestatic and Fibrotic Diseases
EA201690513A1 (ru) Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний
EA201891946A1 (ru) Коагонисты глюкагона и glp-1 для лечения ожирения
CL2017002774A1 (es) Secuencias de uricasa mejorada y métodos de tratamiento
EA201791199A1 (ru) Способ лечения болезни альцгеймера
BR112017026061A2 (pt) composto, uso de um composto, e, método de tratamento de uma infecção viral
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
EA201892287A1 (ru) Фармацевтические комбинации для лечения рака
MX2019003235A (es) Metodos para tratar dermatitis atopica severa administrando un inhibidor de receptor de isoleucina-4.
BR112019004299A2 (pt) peptídeos de nnif e relacionados a nnif e métodos relacionados
BR112017002433A2 (pt) anticorpos anticeramida
AU2015267099A8 (en) Use of eribulin in the treatment of cancer
EA201692402A1 (ru) Лекарственные формы для местного применения и их использование
BR112017027277A2 (pt) ?método para o tratamento ou prevenção de uma doença e métodos para matar uma célula?
CY1122374T1 (el) Βιοτινη για την θεραπευτικη αντιμετωπιση απομυελινωτικων νευροπαθειων

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]